Table 1.
Effect of ZMS treatment on EAC-bearing mice.
| Parameters | Treatment of different groups | ||||||
|---|---|---|---|---|---|---|---|
| Control | EAC | EAC + 5FU | EAC + ZMS | EAC + ZMS | EAC + ZMS | EAC + ZMS | |
| Dose (mg/kg b.wt.) | 20 | 100 | 200 | 400 | 800 | ||
| Hb content (mg/dl) | 13 ± 0.5 | 9.5 ± 0.73a | 13.1 ± 0.4b | 11.24 ± 0.67b | 11.59 ± 0.6b | 12.4 ± 0.81b | 12.2 ± 0.45b |
| WBC (cells/mL × 106) | 7.17 ± 0.11 | 15.6 ± 0.64a | 7.73 ± 0.68a | 12.1 ± 0.75b | 9.4 ± 0.83b | 9.2 ± 1.26b | 8.5 ± 0.40b |
| RBC (cells/mL × 106) | 5.33 ± 0.45 | 3.5 ± 0.41a | 5.2 ± 0.11b | 4.2 ± 0.55b | 4.3 ± 0.35b | 4.9 ± 0.15b | 5.0 ± 0.12b |
| Tumor Volume (mL) | — | 8.3 ± 0.79 | 0.7 ± 0.20b | 7.6 ± 0.94b | 5.4 ± 0.96b | 4.5 ± 1.04b | 2.1 ± 0.51b |
| Viable tumor Cell Count (×107) | — | 283.02 ± 1.63 | 11.17 ± 0.96b | 186.12 ± 1.57b | 146.27 ± 1.43b | 109.57 ± 1.08b | 69.59 ± 1.62b |
| Mean Survival time (Days) | — | 20 ± 1.41 | 39 ± 0.81b | 23 ± 1.53b | 26 ± 1.73b | 30 ± 0.81b | 34 ± 1.63 |
| Tumor inhibition (%) | — | 96.11 ± 0.73 | 25.67 ± 1.09 | 39.78 ± 2.55 | 57.54 ± 1.03 | 75.42 ± 0.96 | |
| Increase in life span (%) | — | 95 | 15 | 30 | 50 | 70 | |
The results are presented as Mean ± S.E.M. (n = 10). a P < .001 in comparison to normal group; b P<.05 in comparison to EAC control group.